Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Development trends for therapeutic antibody fragments

Nature Biotechnology volume 27, pages 331–337 (2009)Cite this article

Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Distribution of fragment type across developmental categories.
Figure 3: Distribution of clinical indications across developmental categories.
Figure 4: Molecular classes of fragment therapeutics in preclinical research and clinical development.

References

  1. Reichert, J.M. Curr. Pharm. Biotechnol. 9, 423–430 (2008).

    Article  CAS  Google Scholar 

  2. Maggon, K. Curr. Med. Chem. 14, 1978–1987 (2007).

    Article  CAS  Google Scholar 

  3. DataMonitor. Monoclonal Antibodies Report Part II: Companies—Holding mAbs in Portfolio Promises Protection Against the Looming 2011–2012 Patent Cliff (DataMonitor, New York, 2007).

  4. Humphreys, A. MedAdNews 27, 12–33 (2008).

    Google Scholar 

  5. Reichert, J.M., Rosensweig, C.J., Faden, L.B. & Dewitz, M.C. Nat. Biotechnol. 23, 1073–1078 (2005).

    Article  CAS  Google Scholar 

  6. Inbar, D., Hochman, J. & Givol, D. Proc. Natl. Acad. Sci. USA 69, 2659–2662 (1972).

    Article  CAS  Google Scholar 

  7. Better, M., Chang, C.P., Robinson, R.R. & Horwitz, A.H. Science 240, 1041–1043 (1988).

    Article  CAS  Google Scholar 

  8. Bird, R.E. et al. Science 242, 423–426 (1988).

    Article  CAS  Google Scholar 

  9. Abuchowski, A., McCoy, J.R., Palczuk, N.C., van Es, T. & Davis, F.F. J. Biol. Chem. 252, 3582–3586 (1977).

    CAS  PubMed  Google Scholar 

  10. Holliger, P. & Hudson, P.J. Nat. Biotechnol. 23, 1126–1136 (2005).

    Article  CAS  Google Scholar 

  11. Harmsen, M.M. & De Haard, H.J. Appl. Microbiol. Biotechnol. 77, 13–22 (2007).

    Article  CAS  Google Scholar 

  12. Jain, R.K. Cancer Res. 50, 814s–819s (1990).

    CAS  PubMed  Google Scholar 

  13. Ward, E.S., Gussow, D., Griffiths, A.D., Jones, P.T. & Winter, G. Nature 341, 544–546 (1989).

    Article  CAS  Google Scholar 

  14. Yokota, T., Milenic, D.E., Whitlow, M. & Schlom, J. Cancer Res. 52, 3402–3408 (1992).

    CAS  PubMed  Google Scholar 

  15. Jain, R.K. Cancer Res. 47, 3039–3051 (1987).

    CAS  PubMed  Google Scholar 

  16. Jain, R.K. & Baxter, L.T. Cancer Res. 48, 7022–7032 (1988).

    CAS  PubMed  Google Scholar 

  17. Neuwelt, E.A. et al. Cancer Res. 48, 4725–4729 (1988).

    CAS  PubMed  Google Scholar 

  18. Fujimori, K., Covell, D.G., Fletcher, J.E. & Weinstein, J.N. Cancer Res. 49, 5656–5663 (1989).

    CAS  PubMed  Google Scholar 

  19. Stijlemans, B. et al. J. Biol. Chem. 279, 1256–1261 (2004).

    Article  CAS  Google Scholar 

  20. Lauwereys, M. et al. EMBO J. 17, 3512–3520 (1998).

    Article  CAS  Google Scholar 

  21. Larson, S.M. et al. J. Clin. Invest. 72, 2101–2114 (1983).

    Article  CAS  Google Scholar 

  22. Schott, M.E. et al. Cancer Res. 52, 6413–6417 (1992).

    CAS  PubMed  Google Scholar 

  23. Arend, W.P. & Silverblatt, F.J. Clin. Exp. Immunol. 22, 502–513 (1975).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Ward, E.S. et al. Mol. Biol. Cell 16, 2028–2038 (2005).

    Article  CAS  Google Scholar 

  25. Woof, J.M. & Burton, D.R. Nat. Rev. Immunol. 4, 89–99 (2004).

    Article  CAS  Google Scholar 

  26. Cumber, A.J., Ward, E.S., Winter, G., Parnell, G.D. & Wawrzynczak, E.J. J. Immunol. 149, 120–126 (1992).

    CAS  PubMed  Google Scholar 

  27. King, D.J. et al. Cancer Res. 54, 6176–6185 (1994).

    CAS  PubMed  Google Scholar 

  28. Hudson, P.J. & Souriau, C. Nat. Med. 9, 129–134 (2003).

    Article  CAS  Google Scholar 

  29. Shimba, N. et al. FEBS Lett. 360, 247–250 (1995).

    Article  CAS  Google Scholar 

  30. Jespers, L., Schon, O., Famm, K. & Winter, G. Nat. Biotechnol. 22, 1161–1165 (2004).

    Article  CAS  Google Scholar 

  31. Wörn, A. & Plückthun, A. J. Mol. Biol. 305, 989–1010 (2001).

    Article  Google Scholar 

  32. Sanz, L., Cuesta, A.M., Compte, M. & Alvarez-Vallina, L. Acta Pharmacol. Sin. 26, 641–648 (2005).

    Article  CAS  Google Scholar 

  33. Huston, J.S. et al. Proc. Natl. Acad. Sci. USA 85, 5879–5883 (1988).

    Article  CAS  Google Scholar 

  34. Skerra, A. & Pluckthun, A. Science 240, 1038–1041 (1988).

    Article  CAS  Google Scholar 

  35. Reichert, J.M. & Valge-Archer, V.E. Nat. Rev. Drug Discov. 6, 349–356 (2007).

    Article  CAS  Google Scholar 

  36. http://www.fda.gov/cder/biologics/review/abcicen110597r2.pdf

  37. http://www.fda.gov/cder/biologics/review/abcicen110597r1.pdf

  38. http://www.fda.gov/cder/foi/nda/2006/125156s0000_Lucentis_MedR.pdf

  39. Steinbrook, R. N. Engl. J. Med. 355, 1409–1412 (2006).

    Article  CAS  Google Scholar 

  40. http://www.fda.gov/cder/foi/nda/2008/125160s000_SumR.pdf

Download references

Author information

Author notes

  1. Janice M. Reichert is at Tufts Center for the Study of Drug Development, Boston, Massachusetts, USA. janice.reichert@tufts.edu

Authors and Affiliations

  1. Aaron L. Nelson is at Tufts University School of Medicine, Boston, Massachusetts, USA and,

    Aaron L Nelson & Janice M Reichert

Authors
  1. Aaron L Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janice M Reichert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelson, A., Reichert, J. Development trends for therapeutic antibody fragments. Nat Biotechnol 27, 331–337 (2009). https://doi.org/10.1038/nbt0409-331

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0409-331

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing